Coelenterazine h 2-monooxygenase Antibody

What is Coelenterazine h 2-monooxygenase and why is it important in research?

Coelenterazine h 2-monooxygenase (EC 1.13.12.5), also known as Renilla-luciferin 2-monooxygenase or Renilla-type luciferase, is an enzyme derived from the sea pansy (Renilla reniformis). This enzyme catalyzes the oxidation of coelenterazine substrate through a complex biochemical pathway that results in bioluminescence. The reaction begins with substrate binding, followed by an oxygenation producing a short-lived hydroperoxide that forms a dioxetanone structure. This structure collapses, releasing CO₂ and generating approximately 50 kcal/mole of energy needed to create an excited coelenteramide product . The enzyme serves as a critical reporter in numerous experimental systems including gene expression assays, protein-protein interaction studies, and live cell imaging applications .

How does the bioluminescence mechanism of Coelenterazine h 2-monooxygenase differ in vivo versus in vitro?

The bioluminescence mechanism shows significant variation between in vivo and in vitro conditions. In the natural in vivo environment within Renilla reniformis, the excited coelenteramide product (specifically the singlet form of the monoanion) undergoes nonradiative energy transfer to an accessory green fluorescent protein (GFP). This energy transfer results in the emission of green bioluminescence characteristic of sea pansies in their natural habitat . In contrast, when the enzyme operates in vitro without the presence of the GFP accessory protein, the excited coelenteramide directly emits blue light . This distinction is crucial for researchers designing experimental systems, as the spectral properties will vary depending on whether the native GFP is present or if the luciferase is being used in isolation .

What is the molecular structure and sequence of Coelenterazine h 2-monooxygenase?

Coelenterazine h 2-monooxygenase from Renilla reniformis is encoded by the protein sequence identified by UniProt ID P27652 . The complete amino acid sequence consists of 311 residues:

MTSKVYDPEQRKRMITGPQWWARCKQMNVLDSFINYYDSEKHAENAVIFLHGNAASSYLWRHVVPHIEPVARCIIPDLIGMGKSGKSGNGSYRLLDHYKYLTAWFELLNLPKKIIFVGHDWGACLAFHYSYEHQDKIKAIVHAESVVDVIESWDEWPDIEEDIALIKSEEGEKMVLENNFFVETMLPSKIMRKLEPEEFAAYLEPFKEKGEVRRPTLSWPREIPLVKGGKPDVVQIVRNYNAYLRASDDLPKMFIESDPGFFSNAIVEGAKKFPNTEFVKVKGLHFSQEDAPDEMGKYIKSFVERVLKNEQ

The protein contains critical catalytic domains that facilitate substrate binding and the subsequent oxygenation reaction. Structural studies have revealed that the enzyme adopts a conformation that creates a hydrophobic pocket for coelenterazine binding, with key residues positioned to facilitate the oxidation reaction and energy transfer processes .

What are the optimal conditions for using anti-Renilla luciferase antibodies in Western blot applications?

For optimal Western blot detection of Renilla luciferase, researchers should follow a systematic protocol focusing on sample preparation, antibody concentration, and detection parameters. Begin by extracting proteins under non-denaturing conditions using a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, and protease inhibitor cocktail. Separate 20-30 μg of protein extract on a 10% SDS-PAGE gel, followed by transfer to a PVDF membrane .

When using rabbit polyclonal antibodies such as ab187338, optimal dilution ranges from 1:1000 to 1:5000 in 5% non-fat milk blocking solution . For most effective results, primary antibody incubation should occur overnight at 4°C with gentle agitation. After washing with TBST buffer (3 × 10 minutes), apply HRP-conjugated secondary antibody at 1:5000-1:10000 dilution for 1 hour at room temperature. The expected band for Renilla luciferase appears at approximately 36 kDa . For enhanced sensitivity without increased background, incorporate 0.05% Tween-20 in all washing steps and consider using enhanced chemiluminescent substrates with extended incubation times (2-3 minutes) .

How can immunofluorescence techniques be optimized when using fluorophore-conjugated Renilla luciferase antibodies?

Optimization of immunofluorescence techniques with fluorophore-conjugated antibodies such as Alexa Fluor 647 (ab225339) or Alexa Fluor 488 (ab319574) anti-Renilla luciferase requires careful attention to fixation, permeabilization, and antibody concentration. Begin with cells grown on glass coverslips and fix with 4% paraformaldehyde for precisely 10 minutes at room temperature . Overfixation can lead to epitope masking and reduced signal intensity.

For permeabilization, use 0.1% Triton X-100 for 5-7 minutes, followed by thorough PBS washing. Block with 5% normal serum (from the species of the secondary antibody) with 1% BSA for 30-60 minutes. The conjugated antibodies perform optimally at dilutions between 1:100 and 1:500 in blocking buffer, with incubation periods of 1-2 hours at room temperature or overnight at 4°C . For multi-color immunofluorescence, select complementary fluorophores with minimal spectral overlap to enable clear distinction between signals. When using the Alexa Fluor 488 conjugate, avoid GFP-based reporter systems due to overlapping emission spectra, while the Alexa Fluor 647 conjugate (far-red) minimizes interference with most standard fluorescent proteins .

What strategies can be employed for quantitative flow cytometry analysis using anti-Renilla luciferase antibodies?

Quantitative flow cytometry with anti-Renilla luciferase antibodies requires methodical sample preparation and careful antibody titration. Begin with a single-cell suspension (1-5 × 10⁶ cells/mL) and fix with 2-4% paraformaldehyde for 10-15 minutes . For intracellular staining, permeabilize with 0.1% saponin or 0.1% Triton X-100 in PBS for 10 minutes.

For optimal resolution, perform antibody titration experiments using serial dilutions (typically 1:50 to 1:500) of Alexa Fluor 647-conjugated anti-Renilla luciferase antibody (ab225339) . Plot the signal-to-noise ratio against antibody concentration to determine the ideal dilution that maximizes specific signal while minimizing background. Include appropriate compensation controls when performing multicolor experiments to correct for spectral overlap.

The resolution table below provides guidance for antibody dilution optimization:

Use a minimum of 10,000 events per sample for statistical validity, and incorporate appropriate gating strategies to exclude dead cells and debris. For quantitative analysis, convert fluorescence intensity to molecules of equivalent soluble fluorochrome (MESF) using calibration beads .

What are the most common causes of high background when using anti-Renilla luciferase antibodies, and how can they be mitigated?

High background signal when using anti-Renilla luciferase antibodies can stem from multiple sources requiring systematic troubleshooting. Non-specific antibody binding is a primary concern, particularly with polyclonal antibodies like ab187338 . To mitigate this, implement more stringent blocking protocols using 5% BSA with 0.1% cold fish skin gelatin to block hydrophobic interactions. Extend blocking time to 2 hours at room temperature to ensure complete saturation of non-specific binding sites.

Cross-reactivity with endogenous proteins represents another significant source of background. This can be addressed through careful antibody validation using Renilla luciferase-null and overexpression controls in parallel experiments . The following methodological modifications have shown significant improvement in signal-to-noise ratios:

• Increase washing stringency by using 0.1% Tween-20 in TBS/PBS and extending wash durations to 4-5 cycles of 10 minutes each

• Perform antibody pre-adsorption against cell lysates from non-transfected cells

• Decrease primary antibody concentration through systematic titration experiments

• Implement dual blocking with 5% normal serum followed by 2% BSA

• For immunofluorescence applications, include an autofluorescence quenching step using 50 mM NH₄Cl treatment for 10 minutes prior to antibody incubation

Contaminating immunoglobulins in recombinant protein preparations can also contribute to background. Purify recombinant proteins using multiple chromatographic steps or consider epitope-tagged versions of Renilla luciferase that allow alternative detection methods .

How can antibody specificity be validated when studying Renilla luciferase in complex biological systems?

Validating antibody specificity for Renilla luciferase in complex biological systems requires a multi-faceted approach combining genetic, biochemical, and analytical techniques. Begin with genetic validation using CRISPR-Cas9 knockout models alongside wild-type controls to confirm antibody specificity . This represents the gold standard for specificity determination, as signals observed in knockout samples definitively indicate non-specific binding.

Competitive peptide blocking experiments provide another robust validation approach. Pre-incubate the antibody with excess purified Renilla luciferase protein (5-10 μg/mL) for 2 hours at room temperature before application to samples. Specific signals should be competitively inhibited, while non-specific binding remains . For Western blot applications, size validation is critical. Renilla luciferase has a predicted molecular weight of approximately 36 kDa; detection of bands at other molecular weights indicates potential cross-reactivity or protein degradation .

For multiplexed immunofluorescence studies, employ spectral unmixing algorithms to distinguish between specific Renilla luciferase signals and potential autofluorescence or cross-reactivity. This is particularly important when using Alexa Fluor 488-conjugated antibodies, which can overlap with cellular autofluorescence spectra . Additionally, implement parallel detection using two different anti-Renilla luciferase antibodies targeting distinct epitopes (such as rabbit polyclonal ab187338 and rabbit monoclonal EPR17792) . Co-localization of signals provides strong evidence for specificity.

What considerations should be made when designing experiments to study protein-protein interactions involving Renilla luciferase?

Studying protein-protein interactions (PPIs) involving Renilla luciferase requires careful experimental design to distinguish genuine interactions from artifacts. When utilizing split Renilla luciferase complementation assays, consider the following critical parameters:

First, fusion protein design significantly impacts assay performance. Position the luciferase fragments at either N- or C-terminus of your proteins of interest, incorporating flexible linkers (GGGGS)ₙ to minimize steric hindrance. Test multiple configurations as tag positioning can substantially affect protein folding, localization, and interaction capacity .

Expression level control is paramount, as overexpression can drive non-physiological interactions. Implement inducible expression systems (e.g., Tet-On) to titrate protein levels, and validate interactions at near-endogenous expression levels using Western blot quantification with anti-Renilla luciferase antibodies . Include appropriate controls: non-interacting protein pairs as negative controls and known interacting partners as positive controls.

When analyzing interaction dynamics, implement time-resolved experiments with sequential sampling rather than endpoint measurements. This approach can reveal transient interactions that might be missed in steady-state analyses. For cellular compartment-specific interactions, combine luciferase complementation with subcellular fractionation verified by immunofluorescence using anti-Renilla luciferase antibodies conjugated to Alexa Fluor 647 .

The following table summarizes key optimization parameters for Renilla luciferase-based protein interaction studies:

For verification of interactions detected through complementation assays, implement orthogonal methods such as co-immunoprecipitation using anti-Renilla luciferase antibodies (e.g., ab187338) coupled with mass spectrometry analysis .

How does the sensitivity and specificity of anti-Renilla luciferase antibodies compare across different experimental platforms?

For immunofluorescence applications, directly conjugated monoclonal antibodies show superior performance characteristics. The Alexa Fluor 647-conjugated EPR17792 antibody (ab225339) demonstrates exceptional sensitivity, detecting Renilla luciferase expression in cells transfected with as little as 50 ng of expression plasmid . Signal-to-noise ratios are approximately 3-fold higher for these monoclonal conjugates compared to indirect detection systems using unconjugated primary antibodies.

Flow cytometric applications reveal another dimension of performance variation. The following comparative data illustrates detection sensitivity across platforms:

For quantitative applications requiring absolute standardization, reference standards of purified Renilla luciferase should be included in each experimental run. When transitioning between experimental platforms, antibody concentrations should be re-optimized rather than directly transferred from established protocols .

What are the advantages and limitations of using anti-Renilla luciferase antibodies compared to direct bioluminescence detection?

Comparing anti-Renilla luciferase antibody-based detection with direct bioluminescence reveals complementary strengths and limitations that inform experimental design choices. Direct bioluminescence detection using coelenterazine substrate offers exceptional sensitivity, with detection limits reaching 10⁻¹⁸ moles of luciferase in optimized systems . This approach provides real-time measurements in living cells or animals with minimal background, enabling temporal studies of gene expression or protein dynamics.

In contrast, antibody-based detection offers distinct advantages. The ability to detect Renilla luciferase in fixed, permeabilized, or denatured samples enables spatial localization studies through immunohistochemistry or immunofluorescence. This approach permits retrospective analysis of stored samples and is compatible with multiplexed detection alongside other proteins of interest .

The following comparative analysis highlights key differences:

For comprehensive experimental approaches, these methods can be integrated sequentially: first utilizing bioluminescence for kinetic measurements in living systems, followed by antibody-based detection for spatial localization and interaction studies .

How should experimental controls be designed when using anti-Renilla luciferase antibodies in complex biological systems?

Designing rigorous control strategies for anti-Renilla luciferase antibody applications in complex biological systems requires a hierarchical approach addressing multiple potential sources of experimental variability and artifact. Primary validation controls should include parallel analysis of samples from both Renilla luciferase-expressing and non-expressing systems. For transfection studies, empty vector controls processed identically to luciferase-expressing samples are essential to distinguish specific antibody binding from transfection-related artifacts .

Antibody specificity controls must be systematically implemented. Include secondary-only controls to assess non-specific binding of detection reagents, and consider pre-immune serum controls when using polyclonal antibodies like ab187338 . For monoclonal antibodies, isotype-matched control antibodies directed against irrelevant epitopes should be tested at equivalent concentrations.

The following hierarchical control framework ensures comprehensive experimental validation:

• Expression system controls:

  • Positive: Cells overexpressing Renilla luciferase

  • Negative: Non-transfected parental cells

  • Dose-response: Titration of expression levels

• Antibody specificity controls:

  • Primary antibody omission

  • Secondary antibody only

  • Isotype/pre-immune controls

  • Competitive blocking with purified antigen

  • Cross-adsorbed antibody preparations

• Technical validation controls:

  • Loading/normalization controls (β-actin, GAPDH)

  • Subcellular fractionation markers

  • Signal linearity assessment across dilution series

  • Replicate consistency evaluation

For studies involving tissue samples or complex biological systems, implement anatomical controls by comparing regions expected to express the transgene versus those that should not. When possible, include genetic knockout or knockdown systems as definitive negative controls .

For quantitative applications, standard curves using purified Renilla luciferase protein at known concentrations (typically 0.1-100 ng) should be processed alongside experimental samples. This enables conversion of signal intensity to absolute protein quantities and facilitates cross-experimental normalization .

How can anti-Renilla luciferase antibodies be effectively used in multiplexed imaging systems?

Implementing multiplexed imaging systems with anti-Renilla luciferase antibodies requires strategic selection of complementary detection reagents and advanced imaging protocols. For optimal spectral separation in multicolor immunofluorescence, pair Alexa Fluor 647-conjugated anti-Renilla luciferase antibodies (ab225339) with fluorophores emitting in green and orange spectrum ranges (e.g., Alexa Fluor 488 and Alexa Fluor 555 conjugates targeting other proteins of interest) . This combination minimizes spectral overlap while maximizing signal distinction.

For highly multiplexed imaging (>4 targets), implement sequential detection protocols using antibody stripping and reprobing. Validate complete stripping efficiency using secondary-only controls between cycles. Alternative approaches include spectral unmixing with hyperspectral imaging systems, which can distinguish overlapping fluorophores based on their unique spectral signatures .

When combining Renilla luciferase detection with endogenous fluorescent proteins, select Alexa Fluor 647 conjugates (ab225339) to avoid spectral overlap with common reporters like GFP, YFP, and mCherry. For subcellular co-localization studies, supplement antibody staining with specific organelle markers:

For tissue-level multiplexed imaging, implement tyramide signal amplification (TSA) to enhance detection sensitivity of low-abundance Renilla luciferase. This approach provides 10-50 fold signal enhancement while maintaining specificity, enabling detection of minimally expressed reporter constructs .

Advanced clearing techniques like CLARITY or CUBIC can be combined with anti-Renilla luciferase immunostaining for whole-tissue 3D reconstruction of expression patterns. When implementing these approaches, optimize antibody concentration (typically requiring 2-3 fold higher concentrations) and extend incubation times to 48-72 hours to ensure complete tissue penetration .

What methodological approaches can enhance detection sensitivity when studying low expression levels of Renilla luciferase?

Enhancing detection sensitivity for low-abundance Renilla luciferase requires integrated optimization of sample preparation, antibody incubation, and signal amplification strategies. Begin by implementing epitope retrieval techniques specifically optimized for luciferase detection. For fixed tissue samples, heat-mediated retrieval in sodium citrate buffer (pH 6.0) at 95°C for 20 minutes significantly improves antibody accessibility to Renilla luciferase epitopes, enhancing detection by 2-5 fold .

Signal amplification technologies substantially extend detection limits. Tyramide signal amplification (TSA) applied to anti-Renilla luciferase detection can lower detection thresholds by approximately 50-fold compared to conventional immunodetection. This approach is particularly valuable for tissue sections or cells expressing Renilla luciferase under weak promoters . For Western blot applications, enhance chemiluminescence detection using extended duration ECL substrates with low background characteristics.

The following protocols show progressive sensitivity enhancement:

• Standard Protocol:

  • Primary antibody (1:1000, overnight 4°C)

  • Secondary antibody (1:5000, 1 hour RT)

  • Detection limit: ~5 ng protein

• Enhanced Protocol:

  • Epitope retrieval (citrate buffer, pH 6.0)

  • Extended primary antibody (1:500, 48 hours 4°C)

  • High-sensitivity secondary (1:2000, 2 hours RT)

  • Extended substrate incubation (5 minutes)

  • Detection limit: ~1 ng protein

• Maximum Sensitivity Protocol:

  • Epitope retrieval (citrate buffer, pH 6.0)

  • Signal enhancing boost solution pre-treatment

  • Concentrated primary antibody (1:250, 72 hours 4°C)

  • TSA amplification system

  • Detection limit: ~100 pg protein

For immunoprecipitation-based enrichment prior to detection, optimize antibody-to-bead ratios. Empirical testing has shown that 5 μg of anti-Renilla luciferase antibody (ab187338) coupled to 50 μL of Protein G magnetic beads provides optimal enrichment from lysates containing low abundance target .

For flow cytometric applications with rare events, implement pre-enrichment using magnetic separation with antibody-conjugated beads followed by multiparameter analysis with directly conjugated Alexa Fluor 647 anti-Renilla luciferase (ab225339). This sequential approach can reliably detect populations representing as little as 0.01% of total cells .

What emerging technologies and methodological innovations are enhancing the utility of anti-Renilla luciferase antibodies in research?

Emerging technologies are revolutionizing anti-Renilla luciferase antibody applications across multiple research domains. Single-cell proteomics platforms now integrate anti-Renilla luciferase detection with mass cytometry (CyTOF) using metal-conjugated antibodies. This approach enables simultaneous quantification of Renilla luciferase reporter expression alongside dozens of cellular markers at single-cell resolution, providing unprecedented insight into cellular heterogeneity in reporter systems .

Advanced microscopy technologies significantly expand spatial analysis capabilities. Lattice light-sheet microscopy combined with Alexa Fluor 647-conjugated anti-Renilla luciferase antibodies (ab225339) enables live-cell super-resolution imaging of Renilla luciferase-tagged proteins with minimal phototoxicity . This approach reveals nanoscale dynamics of fusion proteins while maintaining cell viability for extended imaging periods.

Proximity-based labeling technologies represent another frontier. By conjugating anti-Renilla luciferase antibodies to engineered peroxidases like APEX2, researchers can catalyze local biotinylation of proteins in close proximity to Renilla luciferase-tagged targets. This methodology enables unbiased identification of protein interaction networks surrounding the tagged protein of interest .

Recent innovations in antibody engineering have produced nanobodies against Renilla luciferase with exceptional specificity and tissue penetration. These smaller binding proteins (approximately 15 kDa versus 150 kDa for conventional antibodies) enable more efficient penetration into tissues and dense cellular structures, while their single-domain nature facilitates direct genetic fusion to fluorescent proteins for live-cell applications .

The integration of anti-Renilla luciferase antibodies with spatial transcriptomics platforms represents a particularly promising direction. By combining immunodetection of Renilla luciferase with in situ sequencing or spatial barcoding techniques, researchers can correlate reporter protein expression with comprehensive transcriptional profiles across tissue architectures. This integrated approach bridges the gap between reporter activity and underlying gene expression networks, providing mechanistic context for observed phenotypes .

Computational advances in image analysis further enhance utility. Machine learning algorithms trained on anti-Renilla luciferase immunofluorescence data can automatically identify subcellular localization patterns, quantify expression levels across heterogeneous cell populations, and detect subtle changes in reporter distribution that might be overlooked by manual analysis .